This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
by Zacks Equity Research
Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.
SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion
by Zacks Equity Research
Sarepta's shares sink as second Elevidys-linked death triggers safety concerns, dosing halts and trial pauses.
FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector
by Zacks Equity Research
With FDA platform technology designation for its viral vector, SRPT can fast-track other therapies using the same gene-delivery method.
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
by Zacks Equity Research
Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.
FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch
by Zacks Equity Research
GSK's NDA for linerixibat, for treating itch in PBC patients, gets FDA review with a decision due in March 2026.
Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 65.2% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is it a Good Idea to Invest in Immunocore Stock Right Now?
by Zacks Equity Research
IMCR revenues surge on robust Kimmtrak sales performance. The momentum is likely to continue in 2025.
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Immunocore (IMCR) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Puma Biotechnology beats on first-quarter 2025 earnings and sales. Stock rises in after-hours trading
New Strong Buy Stocks for May 8th
by Zacks Equity Research
BTSG, NWFL, MNRO, UBSI and IMCR have been added to the Zacks Rank #1 (Strong Buy) List on May 8, 2025.
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
by Zacks Equity Research
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. Stock falls.
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Immunocore (IMCR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks
by Zacks Equity Research
CRSP reports wider-than-expected first-quarter loss. Revenues also miss estimates. Stock tanks 12%.
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall
by Zacks Equity Research
Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025. Stock down.
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened
by Zacks Equity Research
Vertex reports weaker-than-expected first-quarter 2025 results. The company tightens its total revenue guidance for 2025.
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
by Zacks Equity Research
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates
by Zacks Equity Research
ALKS' earnings and revenues lag first-quarter 2025 estimates. Sales of proprietary products surpass management's expectations.
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates
by Zacks Equity Research
AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.
Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 107.5% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
by Zacks Equity Research
RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last?
by Zacks Equity Research
Immunocore (IMCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates
by Zacks Equity Research
Puma Biotechnology beats on fourth-quarter 2024 earnings and sales. The company issues a fresh financial guidance for 2025.
United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat
by Zacks Equity Research
UTHR beats fourth-quarter estimates for both earnings and sales. Tyvaso sales fall short of estimates. Stock down in pre-market trading.
Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales
by Zacks Equity Research
BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive.